NewGene Clinical Services - Transfer of Diagnostic Services

In response to NHS England’s recent Strategy and Service Specification for the future of Genomics services in England, NewGene Limited, Newcastle upon Tyne Hospitals, Leeds and Sheffield Hospitals have entered into a partnership to provide services for Yorkshire and the North East Genomic Hub– known as the YNEGLH (Genetic Laboratory Hub).

As a result of this reconfiguration and consolidation, the diagnostic services currently being provided by NewGene Ltd will be transferred to the Newcastle upon Tyne Hospitals NHS Foundation Trust, as part of the YNEGLH, with effect from 1 April 2019. The NewGene laboratories have been transferred into the Northern Genetics Service laboratories and will therefore also be managed by Newcastle Hospitals.

Due to this change in service provider the tests currently provided by NewGene under ISO 15189 will fall out of scope for a period of time. We would like to make all users aware that we are currently working alongside the Northern Genetics Service, who are currently accredited to ISO 15189, and UKAS to ensure that an extension to scope application is undertaken as a priority. They will continue to offer the same high quality service during this time.

Financial arrangements for the period of April 2019 to March 2020 will be unaffected and where tests are currently invoiced on a per test basis this will continue. Invoices for these services will be raised by Newcastle Hospitals directly.

Revised referral forms are available in the downloads section of this website.

If you have any questions about this change in service delivery, please contact:
Jane Lisgo, NewGene Laboratory Manager - , or
Dr David Bourn, Northern Genetics Service Head of Laboratory -

Medulloblastoma sub-typing assay launched

Improving the quality of care delivered to patients

NewGene are delighted to announce availability of an innovative clinical assay to perform molecular sub-typing in cases of medulloblastoma, the most frequently occurring paediatric brain tumour. Developed in collaboration with Professor Steve Clifford and his colleagues at Newcastle University, the test utilises the Agena Bioscience MassARRAY platform to identify characteristic patterns of gene methylation in biopsy samples. This information can provide valuable guidance to clinical teams as they consider the best course of treatment for individual patients.

Additional information about the test and how to submit samples is available

on the medulloblastoma sub-typing page.

PROSPECT-NE: Bringing state of the art tumour profiling to the region

NewGene are part of a project to deliver crucial cancer research

In many areas of cancer we are seeing advances that allow the delivery of personalised or precision medicine with novel agents specifically targeted at the genetic changes causing disease. The PROSPECT-NE study is harnessing the expertise in next generation DNA sequencing at NewGene to enable the Sir Bobby Robson Cancer Trials Research Centre to continue to play a leading role in the development of new cancer treatments.

From December 2017 patients referred to the trials unit will be offered the opportunity to have their tumours profiled to identify any mutations in a panel of genes known to be associated with cancer. This will support signposting of the patients to appropriate clinical trials and add to the knowledge base on the causes of cancer.

To find out more about PROSPECT-NE please click this link.

Industry Focus:

Biomarkers in Personalised Medicine: discovery and delivery

Writing in The Biochemist, NewGene contribute to the conversation on the challenges of biomarker discovery and implementation in a clinical setting.

Click here to view a pdf of the article.

The great success of NewGene User Group Meetings

Over the course of the spring months NewGene have held a number of user group meetings, bringing together our customers, regional clinical experts and the NewGene team to discuss the state of the art in each clinical field and to define how to implement service development and best practice to the processes in our region.

  • EGFR User group meeting, sponsored by Astra Zeneca
  • RAS User group meeting, sponsored by Merck Serono
  • Haematology User group meeting, sponsored by NewGene

Contact us

NewGene Limited
Bioscience Building
International Centre for Life
Newcastle upon Tyne

Tel: +44 (0)191 241 8769
Fax: +44 (0)191 241 8799

Click here for location map

Mon – Fri 08:30 to 17:00, closed Bank Holidays

An ISO 15189 accredited Medical Laboratory company

NewGene Limited | Company Number: 06735445

Technology Partners

Agilent Technologies

Agena Bioscience


Sophia Genetics



Enquiry form